<DOC>
	<DOC>NCT00348023</DOC>
	<brief_summary>Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>· Male or female &gt; 18 years of age Diagnosis of primary openangle glaucoma or ocular hypertension Untreated IOP &gt; 18 mm Hg in each eye at the baseline evaluation Ability to provide informed consent and likely to complete all study visits · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication Uncontrolled systemic disease Active ocular disease other than POAG or ocular hypertension Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted) History of intraocular surgery within the last 3 months Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>